1. Scrip
  2. >>Leadership

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

 
• By Mandy Jackson

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Ionis CEO Brett Monia
Brett Monia was a founding scientist at Ionis • Source: Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. has monetized its expertise in antisense drug discovery by linking up with bigger biopharmaceutical companies to lead late-stage development and commercialization. But going forward, new CEO Brett Monia said, the company will be more selective about entering into new collaborations and prioritize Ionis-owned drug candidates.

Scrip spoke with Monia about Ionis’s future in an interview at the J.P. Morgan Healthcare Conference earlier this month in San Francisco. Monia, a founding scientist of Ionis who most...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.